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Chronic lymphocytic leukemia (CLL) and multiple myeloma areincurable hematologic malignancies that are pathologically linkedwith aberrant nuclear factor-kappa B (NF-κB) activation. In this
study, we identified a group of novel C8-linked benzofused pyrrolo[2,1-
c][1,4]benzodiazepine monomeric hybrids capable of sequence-selective
inhibition of NF-κB with low nanomolar LD50 values in CLL (n=46) and
multiple myeloma cell lines (n=5). The lead compound, DC-1-192, signif-
icantly inhibited NF-κB DNA binding after just 4 h of exposure, demon-
strating inhibitory effects on both canonical and non-canonical NF-κB
subunits. In primary CLL cells, sensitivity to DC-1-192 was inversely cor-
related with RelA subunit expression (r2=0.2) and samples with BIRC3 or
NOTCH1 mutations showed increased sensitivity (P=0.001). RNA-
sequencing and gene set enrichment analysis confirmed the over-repre-
sentation of NF-κB regulated genes in the downregulated gene list.
Furthermore, in vivo efficacy studies in NOD/SCID mice, using a systemic
RPMI 8226 human multiple myeloma xenograft model, showed that DC-
1-192 significantly prolonged survival (P=0.017). In addition, DC1-192
showed synergy with bortezomib and ibrutinib; synergy with ibrutinib
was enhanced when CLL cells were co-cultured on CD40L-expressing
fibroblasts in order to mimic the cytoprotective lymph node microenvi-
ronment (P=0.01). Given that NF-κB plays a role in both bortezomib and
ibrutinib resistance mechanisms, these data provide a strong rationale for
the use of DC-1-192 in the treatment of NF-κB-driven cancers, particular-
ly in the context of relapsed/refractory disease.
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ABSTRACT
Introduction
Nuclear factor kappa B (NF-κB) denotes a family of homo- and heterodimeric
transcription factors composed of five subunits: p65 (RelA), p50, RelB, p52 and c-
Rel.1 These subunits exert their effects via the canonical or non-canonical signaling
pathways.2 NF-κB is maintained in an inactive state in the cytoplasm but following
IκB kinase (IKK) activation NF-κB is shuttled into the nucleus where it exerts its
transcriptional effects.3 NF-κB regulates the transcription of genes that are essential
for cell survival, proliferation, inflammation and invasion/metastasis. These
processes are commonly dysregulated in cancers, including CLL and multiple
myeloma, leading to the constitutive aberrant activation of NF-κB.2-4 Indeed, NF-
κB has been shown to play a central role in disease progression and drug resistance
in these hematologic cancers.5,6 While treatment with currently established thera-
pies, such as the proteasome inhibitor bortezomib or the BTK inhibitor ibrutinib,
are initially effective in a significant proportion of
patients,7,8 there is evidence to suggest that treatment
with both of these agents causes an increase in NF-κB
activation which has been linked to drug resistance and
treatment failure.9,10 Therefore, direct inhibition of NF-κB
could potentially resensitize tumor cells, thus highlight-
ing this transcription factor as a potential therapeutic tar-
get.11-13 
Pyrrolo[2,1-c][1,4]benzodiazepines (PBD) are naturally
occurring molecules produced by Streptomyces bacteria
whose family members include anthramycin (Figure 1)
and tomaymycin.14,15 PBD are a class of sequence-specific
covalent DNA minor groove binding agents that are
selective for GC-rich sequences, and have been evaluated
as potential chemotherapeutic agents in clinical trials.16,17
More recently, members of the PBD family have been
developed as cytotoxic payloads for attachment to anti-
bodies to form antibody-drug conjugates, and a number
of these are currently undergoing clinical evaluation for
the treatment of leukemia and lung cancer.18
This study identified three lead compounds (DC-1-192,
DC-1-92 and DC-1-170) (Figure 1) from a library screen of
87 novel synthetic C8-linked benzofused PBD monomer-
ic hybrids based on their in vitro cytotoxicity. The com-
pounds were then further evaluated for their biological
properties, including differential toxicity, in malignant
and age-matched normal B and T cells. In terms of their
mechanism of action, PBD monomers can recognize and
bind to specific sequences of DNA and therefore have the
potential to act as competitive inhibitors of transcription
factors. Previous research has shown that PBD monomers
such as GWL-78 preferentially inhibit the transcription
factor NF-Y,19 while PBD monomers such as the DC-81-
indole hybrid20 and KMR-28-39 are potent NF-κB
inhibitors.21 The aim of this study was to determine the
biological properties of these novel C8-linked benzofused
PBD monomers by investigating their cytotoxic profiles
in multiple myeloma cell lines, primary CLL cells and age-
matched normal B- and T-lymphocytes. We went on to
investigate their ability to inhibit NF-κB and whether
they could potentiate the effects of the targeted agents
bortezomib and ibrutinib, currently used in the treatment
of myeloma and CLL, respectively.
Methods
Detailed methods can be found in the Online Supplementary
Appendix.
Cell lines, primary chronic lymphocytic leukemia cells
and normal lymphocytes 
Primary CLL cell lines (n=46) and age-matched normal B  and
T cells were obtained with informed consent in accordance with
the ethical approval granted by South East Wales Research
Ethics Committee (02/4806). In addition, five multiple myeloma
cell lines, JJN3, U266, OPM2, MM.1S and H929, were obtained
from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen. The provenance of the cell lines was verified by
multiplex polymerase chain reaction of minisatellite markers; all
were certified mycoplasma-free. 
Measurement of in vitro apoptosis
Apoptosis was assessed using annexin V and propidium
iodide labeling. Samples were analyzed using an Accuri C6 flow
cytometer with CFlow software (BD Biosciences). 
Enzyme-linked immunosorbent assay for NF-κB 
subunits
Nuclear levels of p65, p50, p52 and RelB DNA binding were
assessed in JJN3 and U266 cells treated for 4 h with DC-1-92,
DC-1-170 (0nM 20 nM) and DC-1-192 (0nM 5 nM). 
Synergy with bortezomib and ibrutinib
The synergy between the PBD monomers and bortezomib or
ibrutinib was determined in JJN3 cells and primary CLL cells,
respectively. Fixed molar ratios were derived from experimental-
ly-determined median lethal dose (LD50) values for each PBD and
clinically achievable concentrations of bortezomib and ibrutinib. 
RNA Isolation and sequencing
JJN3 cells were treated with 20 nM of either DC-1-170 or DC-
1-192 for 4 h. RNA was extracted using an RNeasy mini-kit
(Qiagen) in accordance with the manufacturer’s instructions.
Subsequently, 100-900 ng of high-quality total RNA (RNA
integrity number >8) was depleted of ribosomal RNA, and
sequencing libraries were prepared using the Illumina TruSeq
Stranded Total RNA with Ribo-Zero Gold™ kit (Illumina Inc.). 
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Figure 1. The structures of anthramycin and three structurally-related C8-linked benzofused PBD hybrids. Anthramycin (the first PBD to be isolated from a
Streptomyces species), and the three synthetic PBD, DC-1-192, DC-1-92 and DC-1-170, identified as lead compounds in this study.
In vivo systemic xenograft model of myeloma in
NOD/SCID mice
NOD/SCID mice were sublethally irradiated prior to tail vein
inoculation with the human myeloma cell line RPMI8226 (1x107
cells) to initiate tumor development. The date of inoculation
was denoted as day 0. Intravenous treatment with vehicle only;
0.05% dimethylsulfoxide in saline (n=7) or 1 mg/kg of DC-1-192
(n=7) was started at day 5. Survival was evaluated from the first
day of treatment until death. 
Statistical analysis
All statistical analyses were performed using Graphpad Prism
6.0 software (Graphpad Software). The normal distribution of
the data was established using the omnibus K2 test.  Univariate
comparisons were made using the Student t-test for paired and
unpaired observations. All toxicity data from drug treatment
were used to produce sigmoidal dose-response curves from
which LD50 values were calculated. Toxicity data from synergy
experiments were processed using CalcuSyn software with the
median effect method to subsequently calculate the combina-
tion index (CI) for each pair of agents; CI values less <1 were
indicative of synergy.22
Results
Cytotoxic screening of pyrrolo[2,1-c][1,4]benzodi-
azepine compounds identified three lead compounds
Initial cytotoxicity screening (trypan blue exclusion assay)
of a library of 87 novel synthetic C8-linked benzofused PBD
monomeric hybrids was carried out using the multiple
myeloma cell line, JJN3. Three lead compounds were select-
ed for further investigation based on their cytotoxic effects
at nanomolar concentrations. The chemical structures of all
three compounds, together with that of anthramycin on
which they are based, are shown in Figure 1.
In vitro and in vivo cytotoxicity of the lead 
pyrrolo[2,1-c][1,4]benzodiazepine compounds 
in multiple myeloma cell lines
The relative cytotoxicity of the three lead compounds
was then assessed in five different multiple myeloma cell
lines, JJN3, U266, OPM2, MM.1S and H929 using an
annexin V/propidium iodide apoptosis assay. The cells
were cultured for 48 h in increasing concentrations (1 nM-
100 nM) of DC-1-92, DC-1-170 and DC-1-192 and were
compared with untreated controls. Each compound
showed a dose-dependent increase in apoptosis; a repre-
sentative example of the data generated is shown in
Figure 2A. The dose-response curves for each compound
were compared in each cell line using overlaid sigmoidal
plots (Figure 2B) and the mean LD50 values were then cal-
culated for each treatment and plotted on the bar chart
shown in Figure 2C. Although each cell line showed dif-
ferential sensitivity to the three compounds, in every case
DC-1-192 was the most cytotoxic PBD with DC-1-170
showing the least cytotoxicity (Figure 2D). The LD50 val-
ues for DC-1-192 were compared with the published NF-
κB index value for each cell line.23 The NF-κB index is the
average of the log2 values for ten NF-κB-regulated genes
(excluding BIRC3/cIAP2); the higher the index value, the
more NF-κB-dependent the cell line is deemed to be. With
the exception of JJN3 cells, sensitivity to DC-1-192
appeared to be inversely associated with the NF-κB
index, a concept we went on to explore in subsequent
experiments. In order to investigate the anti-tumor effects
of DC-1-192 in vivo, we employed a systemic model of
multiple myeloma in which NOD/SCID mice (2 groups
of 7 mice) were inoculated with the human RPMI 8226
myeloma cell line (1x107 cells). Treatment was initiated 5
days after inocuation with either DC-1-192 (1 mg/kg) or
vehicle control. DC-1-192 was administered once per day
(5 days/week) for 3 weeks by intravenous injection and
animals were monitored daily for morbidity and mortali-
ty. DC-1-192 significantly prolonged the survival of the
mice; the median survival of the DC-1-192-treated mice
was 68 days versus 56 days in untreated mice (hazard
ratio [HR]=2.98; P=0.017) (Figure 2E).
Comparative cytotoxicity in primary chronic 
lymphocytic leukemia and normal B- and T-lymphocytes
Primary CLL cells and age-matched normal B- and T-
lymphocytes obtained from healthy donors were treated
with increasing concentrations of DC-1-92, DC-1-170
and DC-1-192. Apoptosis was measured using
CD19/CD3/annexin V labeling to determine the percent-
age of apoptosis induced by the PBD compunds in CD19+
B cells and CD3+ T cells, as shown in Online Supplementary
Figure S1A. Online Supplementary Figure S1B shows the
comparative dose-responses for each of the cell types
indicating that normal lymphocytes were less susceptible
to the effects of the PBD. As was the case with the three
multiple myeloma cell lines, DC-1-192 was the most
potent cytotoxic agent in primary CLL cells. Online
Supplementary Figure S1C, D shows that CLL cells were
significantly more sensitive to the effects of the PBD than
were age-matched normal B- and T-lymphocytes.
DC-1-192 shows preferential cytotoxicity in chronic
lymphocytic leukemia cells carrying a NOTCH1 or
BIRC3 mutation
All of the CLL samples treated with DC-1-192 (n=46)
showed nanomolar LD50 values with a mean LD50 value for
the entire CLL cohort of 3.8 nM (Figure 3A). We next
examined whether sensitivity to DC-1-192 was associat-
ed with any of the known prognostic markers. There was
no significant difference in mean LD50 value between
IGHV-mutated and IGHV-unmutated samples (Figure
3B); CD38-positive and CD38-negative samples
(≥/<20%) (Figure 3C) and samples with higher or lower
β2-microglobulin concentrations (≥/<3.5 mg/L) (Figure
3D). However, samples derived from patients with a
BIRC3 (n=3) or NOTCH1 (n=11) mutation were signifi-
cantly more sensitive to the effects of DC-1-192 (Figure
3E) suggesting that elevated NF-κB signaling may be a
determinant of sensitivity.24,25 In keeping with this con-
cept, the nuclear expression of the NF-κB subunit p65
(RelA) was inversely correlated with DC-1-192 LD50 val-
ues (Figure 3F).
Nuclear localization of NF-κB subunits following 
treatment with pyrrolo[2,1-c][1,4]benzodiazepines 
We have previously shown that PBD monomers, such
as KMR-28-39, have NF-κB inhibitory effects.21 We, there-
fore, determined the NF-κB inhibitory properties of this
new series of compounds in two myeloma cell lines JJN3
and U266. JJN3 cells overexpress both the canonical and
non-canonical NF-κB subunits and possess an EFTUD2-
NIK fusion gene which lacks the TRAF3 binding domain
resulting in the accumulation of a cytoplasmic EFTUD2-
T. Lewis et al.
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NIK fusion protein. U266 cells exhibit a TRAF3 mutation
causing stabilization of wild-type NIK protein.23,24 Both
cell lines were treated for 4 h with up to 20 nM of each
agent and the relative change in nuclear p65 (RelA), p50,
p52 and RelB DNA binding was determined as a function
of the untreated control. Levels of c-Rel were not evaluat-
ed in this study as JJN3 cells show very low levels of this
subunit relative to the dominant canonical subunits p65
and p50. In JJN3 cells, all the PBD showed significant inhi-
bition of p65, p50 and Rel B but no significant reduction
in p52 (Figure 4A). In contrast, U266 cells showed a sig-
nificant reduction in the nuclear DNA binding of all four
subunits (Figure 4B).
Transcriptional effects of DC-1-170 and DC-1-192 on
JJN3 cells
As predicted, RNA-sequencing analysis of DC-1-170
and DC-1-192 revealed a dominant inhibitory effect on
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Figure 2. PBD induce apoptosis in multiple myeloma cell lines in a dose-depen-
dent manner. (A) An example of annexin V and propidium iodide (PI) bivariate
plots obtained from JJN3 cells treated with increasing concentrations of DC-1-
92. A dose-dependent increase in the proportion of annexin V+/PI- and annexin
V+/PI+ cells was observed. (B) Sigmoidal dose-response curves illustrating the
comparative effects of each compound in U266, OPM2, H929, JJN3 and MM1.S
multiple myeloma cell lines. (C) Comparative analysis of the three lead PBD in
the five multiple myeloma cell lines revealed significant differential sensitivity to
each compound and between each cell line but DC-1-192 was the most potent
PBD in all five cell lines. (D) The relationship between the NF-κB index of each of
the cell lines and their respective mean DC-1-192 LD50 value. (E) In order to inves-
tigate the in vivo antitumor effects of DC-1-192, NOD/SCID mice were systemi-
cally inoculated with the human RPMI 8226 myeloma cell line. DC-1-192 (1
mg/kg) significantly prolonged the survival of the mice when compared to that of
untreated control mice. All in vitro experiments were performed in triplicate and
data are presented as mean ± standard deviation. The in vivo experiment was





gene transcription with a smaller subset of genes showing
increased transcription following exposure to the drug. In
unsupervised hierarchical clustering, the samples clustered
according to treatment condition (Figure 5A). Strikingly,
4,040/5,077 (80%) of the genes altered by exposure to the
drugs were common to both PBD compounds (Figure 5B)
suggesting that their structural similarity resulted in the
inhibition of a conserved set of genes. Furthermore, gene
set enrichment analysis, using WebGestalt (WEB-based
GEne SeT AnaLysis Toolkit),25 confirmed that NF-κB-regu-
lated genes were significantly over-represented in the
downregulated gene list, with a normalized enrichment
score of -1.7750 (Figure 5C, D). These data suggest that
inhibition of NF-κB target genes may contribute to the
cytotoxicity of the PBD compounds. 
Synergy between DC-1-192 in combination with borte-
zomib or ibrutinib
Overexpression of NF-κB is associated with chemother-
apeutic drug resistance in both CLL and multiple myelo-
ma.26,27 Having established that DC-1-192 inhibited
nuclear NF-κB DNA binding and downregulated NF-κB
target genes, we set out to determine whether these
inhibitory properties could enhance the killing effect of
bortezomib and ibrutinib in the JJN3 myeloma cell line
and primary CLL cells, respectively. To investigate syner-
T. Lewis et al.
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Figure 3. DC-1-192 was highly
cytotoxic in primary chronic lym-
phocytic leukemia cells and
showed preferential effects in
BIRC3 and NOTCH1 mutated
samples. (A) All 46 samples test-
ed showed low nanomolar LD50
values when treated with DC-1-
192. (B-D) Analysis of prognostic
subsets revealed that DC-1-192
was equipotent in IGHV mutated
and unmutated samples (B),
CD38-positive and CD38-negative
samples (C) and samples with
high or low concentrations of β2-
microglobulin (D). (E) In contrast,
BIRC3 and NOTCH1 mutated sam-
ples showed significantly
increased sensitivity to DC-1-192.
(F) There was an inverse relation-
ship between nuclear DNA bind-
ing of the canonical NF-κB sub-
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Figure 4. PBD show marked inhibitory effects on both canonical and non-canonical NF-κB subunits. JJN3 and U266 cells were treated with DC-1-92, DC-1-170 and
DC-1-192 for 4 h. Nuclear extracts were then generated from these samples and the amounts of p65, p50, p52 and Rel B were quantified and expressed as relative
fold-change as a function of the untreated controls. (A) JJN3 cells showed significant reductions in nuclear expression of p65, p50 and RelB NF-κB subunits but no
change in p52 following exposure to DC-1-92, DC-1-170 and DC-1-192. (B) In contrast, U266 cells showed significant reductions in nuclear expression of all four NF-
κB subunits. All experiments were performed in triplicate. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. ns: not statistically significant differences. 
A
B
gy, JJN3 and primary CLL cells (n=5) were treated with
increasing concentrations of DC-1-192 both alone and in
combination with bortezomib in JJN3 cells and ibrutinib
in CLL samples. The fixed molar ratios employed in the
combination studies were determined experimentally
using the LD50 values calculated from the previous toxicity
data. The fraction affected plots and isobologram plots
for the drugs and drug combinations in JJN3 cells (Figure
6A), and in primary CLL cells (Figure 6B) show that the
cytotoxic effects of DC-1-192 are potentiated by the
T. Lewis et al.
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Figure 5. RNA sequencing and gene set enrichment analysis revealed that DC-1-170 and DC-1-192 preferentially inhibited NF-κB target genes. (A) Unsupervised
hierarchical clustering revealed a strong drug-associated transcriptional signature for both DC-1-170 and DC-1-192. (B) The majority 4,418/5,077 (87%) of the sig-
nificantly altered transcripts were downregulated in response to drug. Strikingly, 4,040/5,077 (80%) of the changes were common to both DC-1-170 and DC-1-192.
(C) Gene set enrichment analysis showed over-representation of NF-κB target genes in the gene list commonly downregulated by exposure to DC-1-170 and DC-1-
192. (D) The top 12 over-represented pathways in the commonly downregulated gene list following exposure to DC-1-170 and DC-1-192 are shown. The table also




addition of bortezomib and ibrutinib, respectively.
Furthermore, the combination of DC-1-192 with borte-
zomib and ibrutinib showed synergy (CI values <1) at the
level of LD50, LD75 and LD90 with an incremental increase in
synergistic effect from LD50 to LD90 (Figure 6C).
Furthermore, DC-1-192 showed increased synergy with
ibrutinib when primary CLL cells were co-cultured on
CD40L-expressing fibroblasts (Figure 6D) suggesting that
these agents may be particularly effective in the treat-
ment of tissue-resident CLL cells.
Discussion
NF-κB is a master regulator of a number of cellular
processes that contribute to cancer progression, including
cell survival and proliferation. Furthermore, it is often
implicated in drug resistance, highlighting its potential as
a therapeutic target.12,13 The interest in small molecular
DNA-binding agents, such as the PBD monomers, has
increased in recent years due to their ability to selectively
bind to specific sequences within the minor groove of
DNA, a characteristic that separates them from traditional
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Figure 6. DC-1-192 demonstrates cytotoxic synergy with bortezomib and ibrutinib. Synergy between DC-1-192 and bortezomib was experimentally determined in
JJN3 cells and between DC-1-192 and ibrutinib in primary chronic lymphocytic leukemia (CLL) cells. The fixed molar ratios for each combination were derived from
the mean LD50 values for DC-1-192 and the clinically achievable doses of bortezomib and ibrutinib. Apoptosis was determined using the annexin V/propidium iodide
assay. (A) The fraction affected plot and the isobologram plot for DC-1-192, bortezomib and their respective combination (1:15) in JJN3 cells. (B) The fraction affected
plot and isobologram plot for DC-1-192, ibrutinib and their combination (1:3000) in primary cells. (C) The combination indices for the combination DC-1-192 with
bortezomib and DC-1-192 with ibrutinib at the level of LD50, LD75 and LD90 in primary CLL cells (n=5). (D) Comparison of the combination indices generated by the com-
bination of DC-1-192 and ibrutinib in monoculture and CD40L-expressing co-culture. All JJN3 cell line experiments were performed in triplicate. All of the primary
CLL experiments were performed on samples derived from five individual patients with data presented as the mean of duplicate experiments.
A B
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alkylating agents. This raises the possibility that they can
selectively inhibit transcription factors,16 so this study set
out to determine the in vitro and in vivo biological effects of
a series of novel C8-linked PBD-benzofused hybrids.
Initially library screening identified three lead com-
pounds. All three PBD showed high potency in five dif-
ferent multiple myeloma cell lines with LD50 values in the
low nanomolar range. Subsequently, the PBD showed
similar high potency in a cohort of 46 primary CLL sam-
ples and significantly lower toxicity in normal age-
matched B- and T-lymphocytes. The most cytotoxic PBD,
DC-1-192, showed 2.4-fold and 4.6-fold differential toxi-
city in CLL cells suggesting that this compound has a pos-
itive therapeutic index. We went on to show that DC-1-
192 was well tolerated in a systemic in vivo xenograft
model of myeloma and significantly prolonged the sur-
vival of the mice. 
Subset analysis of the CLL cohort data revealed that
DC-1-192 was equipotent in poor prognostic groups
including IGHV unmutated cases (P=0.96). Furthermore,
samples derived from patients with BIRC3 or NOTCH1
mutations showed significantly increased sensitivity to
DC-1-192. These mutations are known to cause aberrant
activation of NF-κB signaling and are associated with
resistance to chemoimmunotherapy and inferior clinical
outcome.28-32 Although these mutations are linked with
non-canonical NF-κB activation, here we showed that
nuclear expression of the canonical p65 subunit was a
predictor of in vitro sensitivity to DC-1-192.    
Given these findings, we plotted the previously pub-
lished NF-κB index for each of the myeloma cell lines23
against their respective LD50 for DC-1-192. Four of the five
cell lines showed an inverse relationship between their
NF-κB index and DC-1-192 LD50 value suggesting that
response to DC-1-192 was influenced by how NF-κB-
dependent the cell lines were. JJN3 cells were the excep-
tion to this rule; these cells had a high NF-κB index (10.8)
but were relatively resistant, in comparison to the other
four cell lines, to the cytotoxic effects of DC-1-192 (mean
LD50 = 6 nM). The reasons for this are likely to be multiple
and may be unrelated to NF-κB, but it is worthy of note
that JJN3 cells possess a cytoplasmic EFTUD2-NIK fusion
gene, which may alter p100 processing to p52. Indeed,
when we assessed the impact of the PBD on nuclear NF-
κB subunit DNA binding in JJN3 cells, all three com-
pounds showed significant inhibition of the p65 and p50
canonical subunits as well as the non-canonical subunit
RelB after 4 h. In contrast, no significant change in p52
was observed following treatment with the PBD. We sub-
sequently repeated the experiments using the U266 cell
line, which has a TRAF3 mutation leading to the cyto-
plasmic accumulation of NF-κB inducing kinase (NIK).23,24
These cells showed a significant reduction in all four NF-
κB subunits including p52 following short-term treatment
with PBD. 
The rapid reduction in nuclear NF-κB subunit expres-
sion indicates that NF-κB inhibition precedes apoptosis in
these cells and may contribute to the efficacy of the PBD.
Given the DNA binding characteristics of these com-
pounds, it seems possible that they compete for NF-κB
binding motifs, thereby inhibiting the transcription of
NF-κB target genes. The reduction in nuclear NF-κB sub-
units observed in this study may have been caused by the
shuttling of unbound NF-κB back to the cytoplasm and/or
targeted degradation.33,34
Activation of NF-κB has also been implicated in the
development of resistance to chemotherapeutic drugs in
myeloma and CLL.35 Several DNA-damaging agents,
including melphalan and fludarabine, have been shown
to induce the activity of NF-κB, thereby contributing to
cellular resistance to the cytotoxic effects of these treat-
ments.6,36 In myeloma, bortezomib has been shown to re-
sensitize malignant cells to the effects of chemotherapy.37
However, the emergence of bortezomib-resistant sub-
clones ultimately leads to relapse in many patients.38 One
putative mechanism of bortezomib resistance is the con-
stitutive expression of NF-κB. Although bortezomib can
prevent de novo activation of the canonical pathway, it has
no significant effect on constitutive NF-κB activity.27 In
this study, we showed that direct competitive inhibition
of NF-κB at the site of transcription led to the re-sensiti-
zation of multiple myeloma cells to the effects of borte-
zomib. This synergistic effect is likely to be multifactori-
al, but indicates that bortezomib and the PBD have differ-
ent molecular targets. 
Similarly, in CLL Bruton tyrosine kinase (BTK) has been
shown to be a critical downstream mediator of B-cell
receptor signaling that is often constitutively activated in
CLL patients. The targeting of this kinase with the BTK
inhibitor, ibrutinib, has shown notable effects in patients
with relapsed CLL39,40 and this is mediated, at least in part,
by the distal inhibition of NF-κB.41 However, emerging
evidence of resistance mechanisms to ibrutinib strongly
implicate NF-κB.42 Here, we show that the combination
of DC-1-192 with ibrutinib produced cytotoxic synergy
suggesting that the PBD and ibrutinib target NF-κB
through different mechanisms and/or that they have
other, non-overlapping, molecular targets. Furthermore,
synergy was enhanced when primary CLL cells were co-
cultured on CD40L-expressing fibroblasts in order to
mimic the lymph node microenvironment. This suggests
that PBD may be particularly useful in targeting tissue-
resident tumor cells.
In summary, the novel PBD compunds evaluated in this
study showed low nanomolar toxicity in both primary
CLL cells and myeloma cell lines. In addition, primary
CLL cells carrying BIRC3 or NOTCH1 mutations were
preferentially sensitive to the cytotoxic effects of DC-1-
192 suggesting that this agent may be a potential thera-
peutic option for these poor-risk subsets. Mechanistically,
the PBD demonstrated promising dual inhibitory proper-
ties on both the canonical and non-canonical NF-κB path-
ways, a characteristic that has been previously linked to
significant antitumor effects in multiple myeloma.43
Furthermore, the PBD showed in vitro synergy with borte-
zomib and ibrutinib in multiple myeloma and CLL,
respectively, providing a strong rationale for the use of
these agents in the treatment of relapsed/refractory B-cell
neoplasms. 
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